Elmind Capital LP Acquires Shares of 900,000 Alector, Inc. $ALEC

Posted by Stanley Muller on Jun 18th, 2026

Elmind Capital LP acquired a new stake in shares of Alector, Inc. (NASDAQ:ALEC – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 900,000 shares of the company’s stock, valued at approximately $1,404,000.

Other hedge funds also recently made changes to their positions in the company. Foresite Capital Management IV LLC acquired a new position in shares of Alector in the 4th quarter worth approximately $6,064,000. Spruce Street Capital LP acquired a new position in shares of Alector in the 4th quarter worth approximately $1,744,000. 683 Capital Management LLC grew its position in shares of Alector by 235.0% in the 4th quarter. 683 Capital Management LLC now owns 3,350,000 shares of the company’s stock worth $5,226,000 after acquiring an additional 2,350,000 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in shares of Alector in the 4th quarter worth approximately $40,000. Finally, Prudential Financial Inc. acquired a new position in shares of Alector in the 2nd quarter worth approximately $30,000. Institutional investors and hedge funds own 85.83% of the company’s stock.

Alector Price Performance

NASDAQ ALEC opened at $1.56 on Thursday. Alector, Inc. has a 52 week low of $1.09 and a 52 week high of $3.40. The company has a current ratio of 5.25, a quick ratio of 5.25 and a debt-to-equity ratio of 0.80. The stock has a market cap of $173.21 million, a price-to-earnings ratio of -1.31 and a beta of 0.61. The company has a 50-day moving average price of $2.16 and a two-hundred day moving average price of $1.96.

Alector (NASDAQ:ALEC – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.08. Alector had a negative net margin of 680.83% and a negative return on equity of 295.17%. The company had revenue of $1.05 million for the quarter, compared to analyst estimates of $9.67 million. Analysts forecast that Alector, Inc. will post -0.86 EPS for the current year.

Insider Activity at Alector

In other Alector news, CFO Neil Lindsay Berkley sold 19,360 shares of the firm’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $1.97, for a total value of $38,139.20. Following the sale, the chief financial officer owned 379,900 shares in the company, valued at approximately $748,403. This trade represents a 4.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Arnon Rosenthal sold 87,216 shares of the firm’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $1.97, for a total transaction of $171,815.52. Following the completion of the sale, the chief executive officer owned 2,367,206 shares in the company, valued at $4,663,395.82. The trade was a 3.55% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 117,580 shares of company stock worth $232,557 in the last 90 days. 8.30% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages have recently commented on ALEC. Weiss Ratings reiterated a “sell (e+)” rating on shares of Alector in a research report on Monday, May 4th. Cantor Fitzgerald upgraded Alector from a “neutral” rating to an “overweight” rating in a research report on Wednesday, April 15th. Wall Street Zen upgraded Alector from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. BTIG Research upgraded Alector from a “neutral” rating to a “buy” rating and set a $6.00 price objective for the company in a research report on Tuesday, March 10th. Finally, Morgan Stanley restated an “underweight” rating and set a $2.00 price objective on shares of Alector in a research report on Monday, May 4th. Three research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $3.63.

Get Our Latest Report on Alector

Alector Company Profile

(Free Report)

Alector is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company is focused on discovering and developing immuno-neurology therapies that target the innate immune system to treat a range of neurodegenerative disorders. Alector’s approach aims to harness the body’s natural defense mechanisms to clear pathological proteins and restore neuronal function in conditions such as Alzheimer’s disease and frontotemporal dementia.

The company’s pipeline includes multiple product candidates in both preclinical and clinical stages, with lead programs AL001 and AL002 advancing in frontotemporal dementia and Alzheimer’s disease studies.